Title | Testosterone and dihydrotestosterone and incident ischaemic stroke in men in the Cardiovascular Health Study. |
Publication Type | Journal Article |
Year of Publication | 2014 |
Authors | Shores, MM, Arnold, AM, Biggs, ML, Longstreth, WT, Smith, NL, Kizer, JR, Cappola, AR, Hirsch, CH, Marck, BT, Matsumoto, AM |
Journal | Clin Endocrinol (Oxf) |
Volume | 81 |
Issue | 5 |
Pagination | 746-53 |
Date Published | 2014 Nov |
ISSN | 1365-2265 |
Keywords | Aged, Aged, 80 and over, Brain Ischemia, Cardiovascular Physiological Phenomena, Dihydrotestosterone, Health, Humans, Incidence, Longitudinal Studies, Male, Stroke, Testosterone |
Abstract | <p><b>OBJECTIVE: </b>Ischaemic stroke is a major cause of morbidity and mortality in elderly men. Our main objective was to examine whether testosterone (T) or dihydrotestosterone (DHT) was associated with incident ischaemic stroke in elderly men.</p><p><b>DESIGN: </b>Cohort study.</p><p><b>PARTICIPANTS: </b>Elderly men in the Cardiovascular Health Study who had no history of stroke, heart disease or prostate cancer as of 1994 and were followed until December 2010.</p><p><b>MEASUREMENTS: </b>Adjudicated ischaemic stroke.</p><p><b>RESULTS: </b>Among 1032 men (mean age 76, range 66-97), followed for a median of 10 years, 114 had an incident ischaemic stroke. Total T and free T were not significantly associated with stroke risk, while DHT had a nonlinear association with incident stroke (P = 0·006) in analyses adjusted for stroke risk factors. The lowest risk of stroke was at DHT levels of 50-75 ng/dl, with greater risk of stroke at DHT levels above 75 ng/dl or below 50 ng/dl. Results were unchanged when SHBG was added to the model. Calculated free DHT had an inverse linear association with incident ischaemic stroke with HR 0·77 (95% CI, 0·61, 0·98) per standard deviation in analyses adjusted for stroke risk factors.</p><p><b>CONCLUSIONS: </b>Dihydrotestosterone had a nonlinear association with stroke risk in which there was an optimal DHT level associated with the lowest stroke risk. Further studies are needed to confirm these results and to clarify whether there is an optimal androgen range associated with the least risk of adverse outcomes in elderly men.</p> |
DOI | 10.1111/cen.12452 |
Alternate Journal | Clin. Endocrinol. (Oxf) |
PubMed ID | 24645738 |
PubMed Central ID | PMC4169352 |
Grant List | U01 HL080295 / HL / NHLBI NIH HHS / United States N01-HC-85081 / HC / NHLBI NIH HHS / United States HL 080295 / HL / NHLBI NIH HHS / United States N01 HC-85079 / HC / NHLBI NIH HHS / United States N01HC55222 / HL / NHLBI NIH HHS / United States N01-HC-85086 / HC / NHLBI NIH HHS / United States N01HC85086 / HL / NHLBI NIH HHS / United States N01-HC-85082 / HC / NHLBI NIH HHS / United States N01 HC-55222 / HC / NHLBI NIH HHS / United States HHSN268201200036C / HL / NHLBI NIH HHS / United States N01-HC-85083 / HC / NHLBI NIH HHS / United States N01-HC-85080 / HC / NHLBI NIH HHS / United States R01 HL080295 / HL / NHLBI NIH HHS / United States N01HC85082 / HL / NHLBI NIH HHS / United States N01HC85083 / HL / NHLBI NIH HHS / United States R01 HL091952 / HL / NHLBI NIH HHS / United States N01-HC-85239 / HC / NHLBI NIH HHS / United States AG-023629 / AG / NIA NIH HHS / United States N01HC85079 / HL / NHLBI NIH HHS / United States R01 AG023629 / AG / NIA NIH HHS / United States 1R01 HL091952 / HL / NHLBI NIH HHS / United States N01HC85080 / HL / NHLBI NIH HHS / United States R56 AG023629 / AG / NIA NIH HHS / United States N01HC85081 / HL / NHLBI NIH HHS / United States |